Pharmaceutical quality of docetaxel generics versus originator drug product: A comparative analysis

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 2019-2033

  Vial, Jérôme ^a,b   Cohen, Mélanie ^a   Sassiat, Patrick ^a   Thiébaut, Didier ^a  

^a Laboratoire Environnement et Chimie Analytique   (France)

^b PSL RESEARCH UNIVERSITY   (France)

Author keywords

Desirability analysis; Docetaxel; Generic; Quality; Reverse phase liquid chromatography; Taxotere

Indexed keywords

AI SU; BOIMEDICS DOCETAXEL; DAXOTEL; DETAXL; DOCEFREZ; DOCELIBBS; DOCETAX; DOCETAXEL; DOCETAXEL COOPER; DOCETERE; DONATAXEL; DOSATAXEL; DOXEL; DOXETAL; DU PA FEI; GENERIC DRUG; LEXUS; NEOTAXEL; OKA DOCETAXEL; ONCODOCEL; ONCOTAXEL; SI QU DI; TEXOT; TRIXOTENE; TX 20; TX 80; ZENOTERE;

AFRICA; AQUEOUS SOLUTION; ARTICLE; ASIA; CHROMATOGRAPHY; COMPARATIVE STUDY; DRUG FORMULATION; DRUG IMPURITY; DRUG QUALITY; MASS; MIDDLE EAST; PH; REVERSED PHASE LIQUID CHROMATOGRAPHY; SOUTH AND CENTRAL AMERICA; STANDARD;

ANTINEOPLASTIC AGENTS; DRUG CONTAMINATION; DRUGS, GENERIC; QUALITY CONTROL; TAXOIDS;

EID: 47949128986     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802207874     Document Type: Article

References (34)

1. Denis JN, Greene AE, Guenard D, et al. Highly efficient, practical approach to natural taxol. J Am Chem Soc 1988;110:5917-9
2. Mangatal L, Adeline MT, Guenard D, et al. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron 1989;45:4177-90
3. Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998;391:199-203
4. Taxotere Summary of Product Characteristics. Available from http://www.emea.europa.eu/humandocs/PDFs/EPAR/taxotere/H-073-PI-en.pdf [Last accessed 4 Oct 2007]
5. Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm Biomed Anal 2004;34:341-8
6. Nightingale CH. A survey of the quality of generic clarithromycin products from 18 countries. Clin Drug Investig 2005; 25:135-52
7. Nightingale CH. A survey of the quality of generic clarithromycin products from 13 countries. Clin Drug Investig 2000; 19:293-305
8. Trefi S, Gilard V, Malet-Martino M, et al. Generic ciprofloxacin tablets contain the stated amount of drug and different impurity profiles: a 19F, 1H and DOSY NMR analysis. J Pharm Biomed Anal 2007;44:743-54
9. US Pharmacopeia. Monograph: paclitaxel injection, 2006
10. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Topic Q3B (R2): impurities in new drug products, 2006, Geneva
11. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Topic Q3A (R2): impurities in new drug substances, 2006, Geneva
12. Rao BM, Chakraborty A, Srinivasu MK, et al. A stability-indicating HPLC assay method for docetaxel. J Pharm Biomed Anal 2006;41:676-81
13. Vasu Dev R, Moses Babu J, Vyas K, et al. Isolation and characterization of impurities in docetaxel. J Pharm Biomed Anal 2006;40:614-22
14. Kumar D, Tomar RS, Deolia SK, et al. Isolation and characterization of degradation impurities in docetaxel drug substance and its formulation. J Pharm Biomed Anal 2007;43:1228-35
15. Le Mapihan K, Vial J, Jardy A. Reversed-phase liquid chromatography testing. Role of organic solvent through an extended set of columns. J Chromatogr A 2005;1088:16-23
16. Wang T. Encyclopedia of chromatography, New York: Marcel Dekker, 2001. pp.245, 691-3
17. Cuadros-Rodríguez L, Bagur-Gonzalez MG, Sanchez-Vinas M, et al. Principles of analytical calibration/quantification for the separation sciences. J Chromatogr A 2007;1158:33-46
18. Vial J, Jardy A. Encyclopedia of Chromatography, New York: Marcel Dekker, 2001, pp.245, 695
19. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Topic Q2 (R1): validation of analytical procedures: text and methodology, 2005, Geneva
20. Massart DL, Vandeginste BGM, Buydens LMC, et al. In: Massart DL, Vandeginste BGM, Buydens LMC, Jong SD, Lewi PJ, Smeyers-Verbeke J, editors. Handbook of chemometrics and qualimetrics: part A. Amsterdam: Elsevier, 1997, pp.788-90
21. Derringer G, Suich R. Simultaneous optimization of several response variables. J Qual Technol 1980;12:214-9
22. Rägo L. Global disequilibrium of quality. In: Prince R, editor. Pharmaceutical quality. River Grove, IL, USA: David Horwood International Publishing Ltd, 2004
23. Layoff T. Drug manufacture, industrial pharmacy considerations, quality assurance, and regulation. A slide program from the Johns Hopkins Bloomberg School of Public Health, 2006. Available from http://ocw.jhsph.edu/courses/ pharmaceuticals managementforunder-servedpopulations/PDFs/Session3.pdf [Last accessed 18 Feb 2007]
24. Newton PN, Green MD, Fernandez FM, et al. Counterfeit anti-infective drugs. Lancet Infect Dis 2006;6:602-13
25. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005;67:2346-53
26. Limaye S, Steele RH, Quin J, et al. An allergic reaction to erythropoietin secondary to polysorbate hypersensitivity. J Allergy Clin Immunol 2002;110:530
27. Kowey PR. Issues in bioequivalence and generic substitution for antiarrhythmic drugs (editorial). Available from http://www.americanheart.org/ presenter.jhtml?identifier=3015266 [Last accessed 18 Feb 2007]
28. Reiffel JA. Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice. Am J Cardiol 2000;85:46-52
29. Gross R. New findings in epilepsy from the 60th Annual Meeting of the American Epilepsy Society: an expert interview. Medscape Neurol Neurosurg 2006;8. Available from http://www.medscape.com/viewarticle/549148 [Last accessed 18 Feb 2007]
30. Crawford P, Feely M, Guberman A, et al. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006;15:165-76
31. Bayer Healthcare Pharmaceuticals. Important Leukine safety information: US market withdrawal and replacement for Liquid Leukine. Available from http://www.fda.gov/CDER/drug/shortages/leukine_DHCP_Instructions_Formulation. pdf [Last accessed 24 Apr 2008]
32. Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001;19:163-9
33. Vial J, Sassiat P, Cohen M, et al. Quality of docetaxel generics versus Taxotere®: a comparative study. 12th International Meeting on Recent Developments in Pharmaceutical Analysis, Island of Elba, Italy, 23-26 September 2007 [abstract P088]
34. Vial J, Sassiat P, Cohen M, et al. Quality of docetaxel generics versus originator drug product: a comparative study. 42nd American Society of Hospital Pharmacy Midyear Clinical Meeting and Exhibition, Las Vegas, NV, USA, 2-7 December 2007 [abstract P543E]